Over-Regulation Is Damaging French Pharma Sector
Industry claims government is reneging on its commitments
Executive Summary
Leem says “Inconsistent and unpredictable” policies are hitting industry’s competitiveness and limiting patients’ access to new medicines.
You may also be interested in...
French Law Tackles Biologic Originator Tactics
France is seeking to tackle the originator tactic of using low prices for biologic brands in hospitals to snare patients and keep them on the same product once they transition to outpatient care, where prices are much higher.
French Law Tackles Biologic Originator Tactics
France is seeking to tackle the originator tactic of using low prices for biologic brands in hospitals to snare patients and keep them on the same product once they transition to outpatient care, where prices are much higher.
French Industry Attacks Price Cut & Drug Shortage Plans
The French government’s plans for more price cuts and new obligations on manufacturers to avert drug shortages will add another layer of complexity to an already complicated operating environment, says the industry.